Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
      Google Scholar   
Citation:
J Clin Oncol vol 21 (6) 976-83
Year:
2003
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
 
Grants:
CA31946  
Corr. Author:
 
Authors:
                                       
Networks:
 
Study
CALGB-9344
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
Adult, Aged, Antibiotics, Antineoplastic, Antineoplastic Agents, Phytogenic, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Disease-Free Survival, Dose-Response Relationship, Drug, Doxorubicin, Female, Humans, Lymphatic Metastasis, Middle Aged, Paclitaxel, Proportional Hazards Models, Treatment Outcome